Century Therapeutics (NASDAQ:IPSC) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Century Therapeutics (NASDAQ:IPSC – Free Report) from a sell rating to a hold rating in a research note published on Saturday.

A number of other research analysts have also issued reports on the stock. Leerink Partners lowered shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 17th. Piper Sandler increased their price objective on Century Therapeutics from $2.00 to $4.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Century Therapeutics in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded Century Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $3.80.

View Our Latest Stock Report on Century Therapeutics

Century Therapeutics Stock Up 6.6%

Shares of NASDAQ:IPSC opened at $2.58 on Friday. The firm has a 50-day simple moving average of $1.09 and a 200 day simple moving average of $0.74. Century Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $2.60. The company has a market cap of $225.49 million, a PE ratio of -8.06 and a beta of 1.72.

Century Therapeutics (NASDAQ:IPSC – Get Free Report) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. As a group, research analysts forecast that Century Therapeutics will post -1.61 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Chad Cowan acquired 58,060 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was acquired at an average price of $0.85 per share, for a total transaction of $49,351.00. Following the completion of the acquisition, the insider directly owned 1,045,087 shares in the company, valued at $888,323.95. This represents a 5.88% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Brent Pfeiffenberger purchased 52,000 shares of the company’s stock in a transaction on Friday, December 12th. The stock was acquired at an average price of $0.58 per share, for a total transaction of $30,160.00. Following the completion of the transaction, the chief executive officer owned 3,322,990 shares of the company’s stock, valued at $1,927,334.20. This represents a 1.59% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders bought 145,060 shares of company stock worth $97,011 and sold 65,987 shares worth $29,798. 4.37% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Prudential Financial Inc. bought a new stake in shares of Century Therapeutics during the 2nd quarter worth $25,000. Qube Research & Technologies Ltd acquired a new position in shares of Century Therapeutics in the 2nd quarter valued at $38,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Century Therapeutics in the 2nd quarter valued at $50,000. Raymond James Financial Inc. purchased a new position in Century Therapeutics in the 2nd quarter worth about $51,000. Finally, AQR Capital Management LLC raised its holdings in Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock worth $53,000 after buying an additional 86,875 shares during the period. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Company Profile

(Get Free Report)

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.

Read More